Development and Application of Treatment for Chikungunya Fever

Overview

Journal Res Rep Trop Med

Publisher Dove Medical Press

Specialty Infectious Diseases

Date 2022 Dec 23

PMID 36561535

Authors

Erin M Millsapps

Emma C Underwood

Kelli L Barr

Affiliations

Soon will be listed here.

Abstract

The development and application of treatment for Chikungunya fever (CHIKF) remains complicated as there is no current standard treatment and many barriers to research exist. Chikungunya virus (CHIKV) causes serious global health implications due to its socioeconomic impact and high morbidity rates. In research, treatment through natural and pharmaceutical techniques is being evaluated for their efficacy and effectiveness. Natural treatment options, such as homeopathy and physiotherapy, give patients a variety of options for how to best manage acute and chronic symptoms. Some of the most used pharmaceutical therapies for CHIKV include non-steroidal anti-inflammatory drugs (NSAIDS), methotrexate (MTX), chloroquine, and ribavirin. Currently, there is no commercially available vaccine for chikungunya, but vaccine development is crucial for this virus. Potential treatments need further research until they can become a standard part of treatment. The barriers to research for this complicated virus create challenges in the efficacy and equitability of its research. The rising need for increased research to fully understand chikungunya in order to develop more effective treatment options is vital in protecting endemic populations globally.

Citing Articles

Assessment of heat-killed expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and .

Patra S, Gajbhiye V, Karpe Y Front Immunol. 2025; 15():1500622.

PMID: 39840038 PMC: 11746998. DOI: 10.3389/fimmu.2024.1500622.

Human health implications of emerging diseases and the current situation in India's vaccine industry.

Behera J, Mishra P, Jena A, Behera B, Bhattacharya M Sci One Health. 2024; 2:100046.

PMID: 39077045 PMC: 11262297. DOI: 10.1016/j.soh.2023.100046.

Unlocking the antiviral potential of rosmarinic acid against chikungunya virus via IL-17 signaling pathway.

Liao X, Xin J, Yu Z, Yan W, Li C, Cao L Front Cell Infect Microbiol. 2024; 14:1396279.

PMID: 38800832 PMC: 11127627. DOI: 10.3389/fcimb.2024.1396279.

Growth in chikungunya virus-related research in ASEAN and South Asian countries from 1967 to 2022 following disease emergence: a bibliometric and graphical analysis.

Sofyantoro F, Frediansyah A, Priyono D, Putri W, Septriani N, Wijayanti N Global Health. 2023; 19(1):9.

PMID: 36747262 PMC: 9901127. DOI: 10.1186/s12992-023-00906-z.

References

Olivon F, Palenzuela H, Girard-Valenciennes E, Neyts J, Pannecouque C, Roussi F . Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. J Nat Prod. 2015; 78(5):1119-28. DOI: 10.1021/acs.jnatprod.5b00116. View

Ledoux A, Cao M, Jansen O, Mamede L, Campos P, Payet B . Antiplasmodial, anti-chikungunya virus and antioxidant activities of 64 endemic plants from the Mascarene Islands. Int J Antimicrob Agents. 2018; 52(5):622-628. DOI: 10.1016/j.ijantimicag.2018.07.017. View

Puntasecca C, King C, LaBeaud A . Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021; 15(3):e0009055. PMC: 7932082. DOI: 10.1371/journal.pntd.0009055. View

de Oliveira B, Carvalho P, Holanda A, Dos Santos R, da Silva F, Barros G . Pilates method in the treatment of patients with Chikungunya fever: a randomized controlled trial. Clin Rehabil. 2019; 33(10):1614-1624. DOI: 10.1177/0269215519856675. View

Constant L, Rajsfus B, Carneiro P, Sisnande T, Mohana-Borges R, Allonso D . Overview on Chikungunya Virus Infection: From Epidemiology to State-of-the-Art Experimental Models. Front Microbiol. 2021; 12:744164. PMC: 8524093. DOI: 10.3389/fmicb.2021.744164. View

Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S . Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009; 200(4):516-23. PMC: 7109959. DOI: 10.1086/600381. View

Mounce B, Cesaro T, Carrau L, Vallet T, Vignuzzi M . Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. Antiviral Res. 2017; 142:148-157. DOI: 10.1016/j.antiviral.2017.03.014. View

Schwameis M, Buchtele N, Wadowski P, Schoergenhofer C, Jilma B . Chikungunya vaccines in development. Hum Vaccin Immunother. 2015; 12(3):716-31. PMC: 4964651. DOI: 10.1080/21645515.2015.1101197. View

Delogu I, Pastorino B, Baronti C, Nougairede A, Bonnet E, de Lamballerie X . In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 2011; 90(3):99-107. DOI: 10.1016/j.antiviral.2011.03.182. View

10.

Suhrbier A . Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev Rheumatol. 2019; 15(10):597-611. DOI: 10.1038/s41584-019-0276-9. View

11.

Teo T, Chan Y, Lee W, Lum F, Amrun S, Her Z . Fingolimod treatment abrogates chikungunya virus-induced arthralgia. Sci Transl Med. 2017; 9(375). DOI: 10.1126/scitranslmed.aal1333. View

12.

Manach C, Scalbert A, Morand C, Remesy C, Jimenez L . Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004; 79(5):727-47. DOI: 10.1093/ajcn/79.5.727. View

13.

Traverse E, Hopkins H, Vaidhyanathan V, Barr K . Cardiomyopathy and Death Following Chikungunya Infection: An Increasingly Common Outcome. Trop Med Infect Dis. 2021; 6(3). PMC: 8293388. DOI: 10.3390/tropicalmed6030108. View

14.

Lidbury B, Rulli N, Suhrbier A, Smith P, McColl S, Cunningham A . Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis. 2008; 197(11):1585-93. DOI: 10.1086/587841. View

15.

Sebastian M, Lodha R, Kabra S . Chikungunya infection in children. Indian J Pediatr. 2009; 76(2):185-9. DOI: 10.1007/s12098-009-0049-6. View

16.

da Cunha R, Trinta K . Chikungunya virus: clinical aspects and treatment - A Review. Mem Inst Oswaldo Cruz. 2017; 112(8):523-531. PMC: 5530543. DOI: 10.1590/0074-02760170044. View

17.

Zaid A, Gerardin P, Taylor A, Mostafavi H, Malvy D, Mahalingam S . Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis Rheumatol. 2017; 70(4):484-495. DOI: 10.1002/art.40403. View

18.

Chan Y, Teo T, Torres-Ruesta A, Hartimath S, Chee R, Khanapur S . Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus Infection. Front Immunol. 2020; 11:894. PMC: 7235449. DOI: 10.3389/fimmu.2020.00894. View

19.

Fernandes A, Souza J, Silva A, Cruz S, Castellano L . Immunoglobulin Therapy in a Patient With Severe Chikungunya Fever and Vesiculobullous Lesions. Front Immunol. 2019; 10:1498. PMC: 6614379. DOI: 10.3389/fimmu.2019.01498. View

20.

Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bezay N, Klingler A . Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis. 2020; 20(10):1193-1203. DOI: 10.1016/S1473-3099(20)30238-3. View